From the clinic to the capital markets, here is Psychedelic Invest's roundup of the key headlines for the week of November 10–16, 2025.
AtaiBeckley Inc. (ATAI): AtaiBeckley posts positive Phase 2b open-label extension data for BPL-003 in treatment-resistant depression
AtaiBeckley reported that a second, 12 mg dose of its intranasal mebufotenin (5-MeO-DMT) candidate BPL-003, given roughly eight weeks after an initial dose, was well tolerated and produced additional rapid, durable antidepressant effects. Pooled active-core patients (n=60) showed a mean MADRS reduction of 19.0 points with a 63% response and 48% remission rate at Day 57. The company said the data support a two-dose regimen heading into a planned Phase 3 program, with an FDA End-of-Phase 2 meeting scheduled and Phase 3 guidance expected in Q1 2026.
Source: ir.ataibeckley.com
Cybin Inc. (CYBN): Cybin reports quarterly results and clinical progress across CYB003 and CYB004 programs
Cybin delivered its quarterly financial results and business update, reiterating that its Phase 2 CYB004 study in generalized anxiety disorder had completed enrollment with topline data expected in Q1 2026, and that dosing continued in the Phase 3 APPROACH study of CYB003 in major depressive disorder. The update underscored the company's late-stage pipeline positioning as it advanced its multinational Phase 3 PARADIGM program for adjunctive MDD treatment.
Source: investingnews.com
MindBio Therapeutics Corp. (MBIO): MindBio's Phase 2b take-home LSD microdosing trial underperforms placebo in major depression
MindBio Therapeutics shared results from its 89-patient Phase 2b trial of repeated take-home microdosed LSD (MB22001) in major depressive disorder, which failed to demonstrate superiority over placebo. The disappointing readout — described by industry observers as the collapse of the largest LSD microdosing program to date — raised fresh questions about the therapeutic value of microdosing relative to full-dose psychedelic approaches being pursued by peers.
Source: thenewswire.com
That's the recap. Follow the Psychedelic Invest Index for how the sector is trading, and check back next week for the next edition.